A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Canakinumab (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Sponsors Novartis
- 21 Nov 2016 Status changed from recruiting to completed.
- 17 Nov 2016 This trial was discontinued in Germany, according to European Clinical Trials Database.
- 05 Apr 2016 Planned End Date changed from 1 Jan 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.